No Data
No Data
Tailong Pharmaceutical (600222.SH) announced first-quarter results, net profit of 21.26 million yuan, an increase of 477.28% year-on-year
Tailong Pharmaceutical (600222.SH) disclosed its report for the first quarter of 2024. The company achieved revenue of 4.9 during the reporting period...
The A-share CRO concept boosted the Penney test by nearly 5%
Glonghui, April 11 | Penicillin tests rose nearly 5%, followed by Tailong Pharmaceutical, Hongbo Pharmaceutical, Haite Biotech, and Blue Biotech.
Investors Shouldn't Be Too Comfortable With Henan Taloph Pharmaceutical StockLtd's (SHSE:600222) Earnings
Henan Taloph Pharmaceutical Stock Co.,Ltd's (SHSE:600222) robust earnings report didn't manage to move the market for its stock. We did some digging, and we found some concerning factors in the detai
Tailong Pharmaceutical (600222.SH): The company did not implement share repurchases in March
Gelonghui, April 1, 丨 Tailong Pharmaceutical (600222.SH) announced that in March 2024, the company did not implement a share repurchase. As of March 31, 2024, the company has repurchased 1,205,200 shares, accounting for 0.21% of the company's total share capital. The highest price of the repurchase transaction was 4.32 yuan/share, the lowest price was 3.82 yuan/share, and the total amount paid was 4,955,198.00 yuan (excluding transaction fees).
Tailong Pharmaceutical (600222.SH) announced its 2023 annual results, with a net profit of 43.56 million yuan, turning a year-on-year loss into a profit
Tailong Pharmaceutical (600222.SH) disclosed its 2023 annual report, and the company achieved revenue of 20 in 2023...
Tailong Pharmaceutical (600222.SH): cumulative repurchase of 1.02 million shares
Gelonghui, March 1, 丨 Tailong Pharmaceutical (600222.SH) announced that as of February 29, 2024, the company had repurchased 1,205,200 shares through centralized bidding transactions, accounting for 0.21% of the company's total share capital. The highest price of the repurchase transaction was 4.32 yuan/share, the lowest price was 3.82 yuan/share, and the total amount paid was 4,955,198.00 yuan (excluding transaction fees).
No Data